pillbase.ru

Aranesp

Active substance: darbepoetin alfa

darbepoetin alfa

Centralised EU authorisationActive

Marketing holder: Amgen Europe B.V.

Verified 2026-10-09 · EMA

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
US 14
  • ARANESP
    INJECTION, SOLUTION · DARBEPOETIN ALFA 150 ug/.3mL
    55513-027
    Amgen, Inc
  • ARANESP
    SOLUTION · DARBEPOETIN ALFA 25 ug/mL
    55513-002
    Amgen, Inc
  • ARANESP
    INJECTION, SOLUTION · DARBEPOETIN ALFA 25 ug/.42mL
    55513-057
    Amgen, Inc
  • ARANESP
    SOLUTION · DARBEPOETIN ALFA 40 ug/mL
    55513-003
    Amgen, Inc
  • ARANESP
    INJECTION, SOLUTION · DARBEPOETIN ALFA 300 ug/.6mL
    55513-111
    Amgen, Inc
All products in this country (14)
Import and control

Control by country

  • United Statesprescription only

    Source: openFDA NDC · record 01a1208c-782a-7d47-8db4-37f4d0cf72c9,01a1208d-4541-7ad9-b658-3ead052b97fc,01a1208d-4545-74ab-9650-476b6cfa1c93,01a1208e-7a06-7d5e-a0c7-0247062b97f7,01a1208e-7a10-79fa-b27f-0b690725a242;count=14 · valid from 2026-10-09 · verified 2026-10-09

More on control status
Registration
Registration number
EMEA/H/C/000332
Registration status
Active
ATC code
B03XA02
Sources
  • product · EMA · EMEA/H/C/000332 · Verified 2026-10-09
  • registration_status · EMA · EMEA/H/C/000332 · Verified 2026-10-09
  • ingredients.0 · EMA · EMEA/H/C/000332 · Verified 2026-10-09